Sub-Directorate General of Surveillance and Response to Public Health Emergencies, Public Health Agency of Catalonia, Generalitat of Catalonia, 08005 Barcelona, Spain.
Unitat de Suport a la Recerca de Catalunya Central, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, 08272 Sant Fruitós de Bages, Spain.
Viruses. 2021 May 14;13(5):908. doi: 10.3390/v13050908.
The use of rapid antigenic tests (Ag-RDTs) to diagnose a SARS-CoV-2 infection has become a common practice recently. This study aimed to evaluate performance of Abbott Panbio Ag-RDTs with regard to nucleic acid amplification testing (NAAT) in the early stages of the disease. A cohort of 149,026 infected symptomatic patients, reported in Catalonia from November 2020 to January 2021, was selected. The positivity rates of the two tests were compared with respect to the dates of symptom onset. Ag-RDTs presented positivity rates of 84% in the transmission phases of the disease and 31% in the pre-symptomatic period, compared to 93% and 91%, respectively, for NAAT. The detection of many false negatives with Ag-RDTs during the pre-symptomatic period demonstrates the risk of virus dissemination with this diagnostic technique if used outside the symptomatic period.
最近,使用抗原快速检测(Ag-RDT)诊断 SARS-CoV-2 感染已成为一种常见做法。本研究旨在评估 Abbott Panbio Ag-RDT 在疾病早期与核酸扩增检测(NAAT)相比的性能。从 2020 年 11 月到 2021 年 1 月,在加泰罗尼亚报告的 149026 例感染症状的患者被选中。比较了两种检测方法与症状发作日期的阳性率。Ag-RDT 在疾病传播阶段的阳性率为 84%,在症状前阶段的阳性率为 31%,而 NAAT 的阳性率分别为 93%和 91%。Ag-RDT 在症状前阶段检测到许多假阴性结果,表明如果在症状期之外使用该诊断技术,存在病毒传播的风险。